Search Results - "McCloskey, T M"

Clinical pharmacology of a novel diarylsulfonylurea anticancer agent by Taylor, C W, Alberts, D S, Ketcham, M A, Satterlee, W G, Holdsworth, M T, Plezia, P M, Peng, Y M, McCloskey, T M, Roe, D J, Hamilton, M

“…LY186641 (diarylsulfonylurea, [DSU]) is a novel anticancer agent because of its unique diarylsulfonylurea chemical structure, broad-spectrum antisolid-tumor…”
Get more information

Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage by BELLAMY, W. T, DALTON, W. S, KAILEY, J. M, GLEASON, M. C, MCCLOSKEY, T. M, DORR, R. T, ALBERTS, D. S

“…Verapamil reversed resistance to doxorubicin in a human multiple myeloma cell line selected for multiple drug resistance. The drug-resistant cell line…”
Get full text

Antitumor activity and clinical pharmacology of sulofenur in ovarian cancer by Taylor, C W, Alberts, D S, Peng, Y M, McCloskey, T M, Matzner, M, Roe, D J, Plezia, P M, Grindey, G B, Hamilton, M, Seitz, D

“…Sulofenur is a diarylsulfonylurea with demonstrated antitumor activity in patients with advanced epithelial ovarian cancer refractory to standard chemotherapy…”
Get more information

High levels of doxorubicin in the tissues of a patient experiencing extravasation during a 4-day infusion by Dorr, R T, Dordal, M S, Koenig, L M, Taylor, C W, McCloskey, T M

“…A 56-year-old patient with multiple myeloma experienced an extravasation of doxorubicin (DOX) and vincristine administered as a 96-hour infusion. An unknown…”
Get more information

A phase I and pharmacokinetic study of intravenous vinzolidine by TAYLOR, C. W, SALMON, S. E, SATTERLEE, W. G, ROBERTONE, A. B, MCCLOSKEY, T. M, HOLDSWORTH, M. T, PLEZIA, P. M, ALBERTS, D. S

“…The semi-synthetic vinca alkaloid vinzolidine was administered to advanced cancer patients as an intravenous bolus on a three day schedule every 21 days…”
Get full text